1. Field of the Invention
This invention is directed to a tamper evident cap assembly that is connectable to a fluid loaded syringe in protective, sealing relation to a nozzle and discharge port of the syringe. A body includes a flow restricting member interconnected to define a one piece construction of the cap assembly. The flow restricting member is structured to facilitate a snap-fit connection of the cap assembly on the syringe, thereby sealing the discharge port thereof. Tampering is indicated by a separation of the flow restricting member and the body and a detachment of the body from the syringe when a predetermined force, sufficient to remove the body from the syringe, is exerted on the body.
2. Description of the Related Art
In hospitals or other medical care facilities, it is common for authorized medical personnel to order that a patient be given a drug or medication by injection. As a result, a number of syringes may be pre-loaded or filled by a pharmacist or other authorized personnel within the hospital or other facility, at a location which may be generally referred to as a syringe filling station. However, such a syringe filling station is typically located in a remote part of the facility, relative to the patient care area where the injection is to be administered. Indeed, at large medical facilities, a syringe filling station may resemble a factory on the hospital grounds from which drug loaded syringes are delivered to multiple nurse's stations in multiple other hospital buildings. Because of the remote location of many nurse's stations, relative to a syringe filling station, a loaded syringe is very often given to another person for delivery to a nurse's station for subsequent dosing of the patient by a duly qualified nurse or other medically trained person.
Also, especially in the case of a very expensive drug or an addictive type of drug that has been prescribed, such as but not limited to morphine, there is a danger that the pre-loaded syringe will be tampered with at some point, by a person seeking to improperly gain unauthorized access to the contents thereof. This possibility can present real danger if such person were to gain access to the prescribed medicine and then, inappropriately and without concern, substitute some other, unauthorized material in the syringe which looks like the actual prescribed medicine and dosage. By way of an example only, if saline solution were substituted for a dose of morphine, this could have extremely serious consequences. Thus, there is a problem of knowing if a sealed, preloaded syringe has, or has not, been exposed to contamination or might otherwise have been compromised by it being tampered with. This and related types of problems have been described in the inventor's own previously granted U.S. Pat. No. 4,667,837 and in other patents, such as U.S. Pat. No. 5,328,474.
However, certain problems remain in the relevant field of art, despite the introduction of products according to those two patents. These include problems of manufacturing such products in a manner which is relatively easy and inexpensive, as well as some problems involved with the assembly and placement onto a drug loaded syringe, such as at a drug filling station. Other problems exist relative to maintaining the sterility during storage at the manufacturing facility of the end caps, and during transport of them to another medical facility, and during storage of them at a medical facility. In summary, the present invention seeks to, address such problems and others associated with the handling of tamper evident end caps during the manufacturing of them, assembly of them and/or use at different stations and/or by different persons.
Accordingly, there is a need in this area for an improved, tamper evident, end cap assembly which is capable of being used with standard or conventional pre-loaded syringes in a manner which overcomes problems and or disadvantages of the type set forth above. If any such improved end cap assembly were developed, it would preferably have certain structural and operative features such as, but not limited to, being at least initially of a one piece construction in order to facilitate appropriate connection to a preloaded syringe. In addition, if any such improved end cap assembly were developed, it would preferably also be structured to provide a clear and unmistakable indication of tampering or of previous access to the contents of the preloaded syringe. Finally, if any such improved, tamper evident end cap assembly were developed, it would ideally also be structurally and operatively reliable, while still remaining relative easy and cost effective to make and assemble, in order to facilitate widespread use and acceptance through out the medical profession.
The present invention is intended to present a solution to these and other needs which remain in the relevant field of art, and as such, is directed to a tamper evident cap assembly structured for being protectively connected to a syringe of the type including a nozzle and a discharge port, with a representative type of conventional syringe from the prior art being shown in
The tamper evident cap assembly of the present invention comprises a body including a nozzle engaging portion defined by a flow restricting member. When the body is connected to the syringe, the flow restricting member is disposed to restrict fluid flow from the discharge port of the nozzle and is cooperatively structured with a remainder of the body to provide a clear indication of an attempted or accomplished access to the contents of the preloaded syringe. In addition, the body and the flow restricting member are further cooperatively structured to at least initially define a one piece construction of the body and flow restricting member.
An attachment assembly is disposed in interconnecting relation between the body and the flow restricting member. Moreover, the attachment assembly may include at least one, but possibly a plurality of attachment members disposed in the aforementioned interconnecting relation and being structured to facilitate disconnection or detachment of the body and the flow restricting member, when a sufficient force is exerted on the body to cause its removal from the syringe. Therefore as generally set forth above, the provision of the frangible or other detachably structured attachment assembly in interconnecting relation between the body and the flow restricting member serves to at least initially define a one piece construction of the tamper evident cap assembly. Such a one piece construction remains in tact prior to the removal of the body from the syringe. However, separation of the body from the flow restricting member and from the syringe nozzle is indicative of attempted access to the contents of the syringe.
In addition, the tamper evident cap assembly also comprises a connecting assembly mounted on the flow restricting member and disposed and structured to retain the flow restricting member on the nozzle of the syringe. As such, the connecting assembly serves to retain the flow restricting member in covering or otherwise flow restricting relation to the discharge port of the nozzle of the syringe, thereby eliminating or restricting the flow of the preloaded drug or fluid within the syringe from exiting through the discharge port. Additional features of the connecting assembly include a cooperative structuring thereof with the nozzle portion of the syringe so as to facilitate a quick, efficient “snap-fit” connection between the flow restricting member and the nozzle. As such, the attachment of the tamper evident cap assembly as well as the removal thereof from a conventional syringe is significantly facilitated by eliminating any need to rotate portions of the tamper evident cap relative to the nozzle during procedures such as, but not limited to, filling and/or refilling procedures performed by a pharmacist or other authorized personnel. It is generally recognized that individuals involved with the prefilling operation of the syringe, which may occur over numerous times over a given period, encounter stressful, operating conditions when significant handling or manipulation of the syringe, is required. Such stressful conditions at least sometimes result in carpel tunnel syndrome or other stress related disorders to the authorized personnel.
Accordingly, the connecting assembly serving to interconnect the flow restricting member and the remaining portions of the body to the syringe is structured to accomplish the aforementioned snap-fit connection to a portion of the nozzle of the syringe by substantially linearly directing the cap assembly towards and onto the nozzle portion when the flow restricting member is substantially coaxially disposed relative to nozzle. More specifically, the preferred snap-fit connection is facilitated due to the provision of a plurality of legs flexibly connected to the flow restricting member. Each of the flexible legs includes a free, distal end having an outwardly projecting lip or like structure formed thereon. Again with reference to the prior art representation of
As a result of such a snap fit connection, the connecting assembly will serve to retain the body of the cap assembly and in particular flow restricting member in enclosing relation with a portion of the nozzle and in flow restricting relation to the discharge port thereof. Accordingly, once the tamper evident cap assembly is operatively positioned on the syringe, a predetermined force being exerted on the body, in attempt to remove it from the syringe will be at least partially transferred to the flow restricting member, resulting in a breakage or detachment of the attachment member or members. This in turn will result in a removal or disconnection of the body of the tamper evident cap assembly from the nozzle of the syringe due to the frangible nature or other breakable structure of the attachment assembly. However, due to the retaining engagement of the connecting assembly with the interior, connecting portion of the nozzle, the flow restricting member will remain on the nozzle in flow restricting relation to the discharge port. Such will be a clear indication that attempts have been made to use the syringe and/or access the contents on the interior thereof.
Upon removal of the body, authorized use of the syringe and/or access to the contents thereof can be accomplished by exerting an additional pulling force on the flow restricting member remaining on the nozzle of the syringe. As such, the lips of the flexible legs of the connecting assembly will be forced from their retaining, biased engagement with the connecting portions of the nozzle of the syringe.
These and other objects, features and advantages of the present invention will become clearer when the drawings as well as the detailed description are taken into consideration.
For a fuller understanding of the nature of the present invention, reference should be had to the following detailed description taken in connection with the accompanying drawings in which:
Like reference numerals refer to like parts throughout the several views of the drawings.
With primary reference to
In order to clearly describe the structural and operative features of the tamper evident cap assembly 20,
Accordingly the cap assembly 20 includes a body 22 having an at least partially hollow interior portion 24 dimensioned to receive the nozzle 2 therein. When the nozzle 2 is disposed within the interior 24, it is substantially surrounded by the cylindrical body 22, when the cap assembly 20 is operatively connected to the syringe 11. As such, the body 22 comprises a substantially cylindrical shell having an open end 26 dimensioned to allow passage therethrough of the nozzle 2 including the nozzle portion or tube 2′. As represented, the nozzle portion 2′ includes an interior channel 3 disposed in communicating relation with the interior of the barrel 1 of the syringe 11. The elongated channel 3 terminates in an open discharge port 4 through which fluid, preloaded into the barrel 1 of the syringe 11, may be discharged. The opposite end 28 of the body 22 is closed in order to prevent access to the nozzle 2 or interior 24 of the body 22 when connected to the nozzle 2 in the intended manner.
More specifically, the opposite or distal end 28 of the body 22 is closed through the provision of an end cap member 30. The end cap member 30 may be fixedly connected in closing or covering relation to the distal end 28 as indicated in
Another structural and operative feature of the present invention comprises the provision of a nozzle engaging portion generally indicated as 40, which is defined by a flow restricting member 42. The nozzle engaging portion 40 and/or flow restricting member 42 is connected directly to the interior 24 of the body 22 by an attachment assembly generally indicated as 44. As such, the body 22 and the flow restricting member 42 define, at least initially, a one piece construction which is connectable to the nozzle 2 of the standard syringe 11 as a single, integrated unit. The attachment assembly 44 may include a base 46 which is fixedly connected to a correspondingly disposed portion of the flow restricting member 42. The connection of the base 46 and the flow restricting member 42 may be by an integral attachment, a secure frictional engagement and/or another appropriate fixed securement. Regardless of the specific type of fixed connection between the base 46 and the corresponding portion of the flow restricting member 42, it is again emphasized that the flow restricting member 42 and the body 22 define a one piece construction of the tamper evident cap assembly 20.
Additional structural features of the attachment assembly 44 include at least one or alternatively, a plurality of attachment members 48 disposed in interconnecting relation between an exterior of the flow restricting member 42 and an interior surface or other interior portion of the body 22. Moreover, one or more of the attachment members 48 are formed of a frangible material or include other breakable or detachable structures which facilitates a detachment of the flow restricting member 42 from the interior of the body 22 when an adequate or predetermine force is applied to the attachment assembly 44 and or body 22. Accordingly, when a predetermined force is applied to the body 22 of sufficient magnitude to remove it from the syringe 11, at least a portion of such force will be transferred to the frangible or breakable material attachment member(s) 48. Therefore, attempts to remove the body 22 from the syringe 11, by applying such a predetermined force, will cause a disconnection of the flow restricting member 42 from the interior surface or other interior portion of the body 22, to which it is interconnected.
As represented, the body 22 is primarily, if not exclusively, secured to the nozzle 2 of the syringe 11 by virtue of the interconnection of the attachment assembly 44 between the flow restricting member 42 and the body 22. As a result, a fracturing or breakage of the one or more attachment members 48, due to a sufficient predetermined force being applied thereto, will cause detachment of the body 22 from the nozzle 2 and most probably a removal of the body 22 from its surrounding, at least partially enclosing relation to the nozzle 2. Moreover, the degree of force required for breakage or detachment of the one or more attachment members 48 is determined and effectively regulated by the material from which the attachment members 48 are formed and/or the number of attachment members utilized. Accordingly, the force required to fracture or break the one or more attachment members 48 should be such as to allow at least a sufficient force to be applied to the body 22 to accomplish its connection, in the intended operative orientation to the nozzle 2, as represented in
With primary reference to
The flexible nature of the legs 52 serve to at least partially facilitate a “snap fit” connection between the nozzle 2 and the legs 52 as they pass into the interior of the nozzle 2 and engage connecting portions 3″ thereof. Such a snap fit connection is accomplished by linearly directing the cap assembly 20 towards the nozzle, such as by applying a substantially linear force to the body in a direction towards the nozzle 2, as schematically indicated by arrow 60. Concurrently, the interior 43 of the flow restricting member 42 is disposed in substantially coaxial alignment with the tube or nozzle portion 2′ of the nozzle 2. The provision of the internal connecting portion or surface 3″ having an at least partially threaded, ribbed or other appropriate structure, will serve to at least partially retain the lips 54 into retaining engagement with the connecting portion 3″. This connection between the flow restricting member 42 and the nozzle 2 will serve to maintain the flow restricting member 42 on the nozzle 2, even when a predetermined force is applied to the exterior of the body 22 in an attempt to remove it from the syringe 11.
As a result of the aforementioned snap fit connection, the connecting assembly 50 will serve to retain the body 22 of the cap assembly 20 and in particular the flow restricting member 42 in enclosing relation with the tube or other nozzle portion 2′ such that the interior 43 of the flow restricting portion 42 is in flow restricting relation to the elongated channel 30 and in particular the discharge port 4. Therefore, the interior 43 of the flow restricting member 42 is dimensioned and configured to snuggly receive and sealingly engage the nozzle tube 2′ therein, such that the discharge port 4 is sealed against discharge of the contents of the preloaded syringe 11.
Once the tamper evident cap assembly 20 is operatively positioned on the nozzle 2, as represented in
Authorized use of this syringe 11 and/or access to the contents thereof can be accomplished by exerting an additional, pulling force or other appropriately directed force on the flow restricting member 42, which will remain attached to the nozzle 2 of the syringe 11. Such application of the pulling or other force will cause the lips 54 of the flexible legs 52 of the connecting assembly 50 to be forced from their retaining, biased engagement with the connecting portion 3″ of the nozzle 2 of the syringe 11.
Since many modifications, variations and changes in detail can be made to the described preferred embodiment of the invention, it is intended that all matters in the foregoing description and shown in the accompanying drawings be interpreted as illustrative and not in a limiting sense. Thus, the scope of the invention should be determined by the appended claims and their legal equivalents.
Now that the invention has been described,
Number | Name | Date | Kind |
---|---|---|---|
3245567 | Knight | Apr 1966 | A |
3747751 | Miller et al. | Jul 1973 | A |
4216872 | Bean | Aug 1980 | A |
4313539 | Raines | Feb 1982 | A |
4420085 | Wilson et al. | Dec 1983 | A |
4571242 | Klein et al. | Feb 1986 | A |
4667837 | Vitello et al. | May 1987 | A |
4726483 | Drozd | Feb 1988 | A |
4832695 | Rosenberg et al. | May 1989 | A |
4844906 | Hermelin et al. | Jul 1989 | A |
5009323 | Montgomery et al. | Apr 1991 | A |
5135496 | Vetter et al. | Aug 1992 | A |
5165560 | Ennis, III et al. | Nov 1992 | A |
5328474 | Raines | Jul 1994 | A |
5458580 | Hajishoreh | Oct 1995 | A |
5558648 | Shields | Sep 1996 | A |
5624402 | Imbert | Apr 1997 | A |
5807343 | Tucker et al. | Sep 1998 | A |
5883806 | Meador et al. | Mar 1999 | A |
6000548 | Tsals | Dec 1999 | A |
6126640 | Tucker et al. | Oct 2000 | A |
6190364 | Imbert | Feb 2001 | B1 |
6193688 | Balestracci et al. | Feb 2001 | B1 |
6196998 | Jansen et al. | Mar 2001 | B1 |
6280418 | Reinhard et al. | Aug 2001 | B1 |
6394983 | Mayoral et al. | May 2002 | B1 |
6485460 | Eakins et al. | Nov 2002 | B2 |
6565529 | Kimber et al. | May 2003 | B1 |
6581792 | Limanjaya | Jun 2003 | B1 |
6585691 | Vitello | Jul 2003 | B1 |
6726652 | Eakins et al. | Apr 2004 | B2 |
6726672 | Hanly et al. | Apr 2004 | B1 |
6921383 | Vitello | Jul 2005 | B2 |
6942643 | Eakins et al. | Sep 2005 | B2 |
7141286 | Kessler et al. | Nov 2006 | B1 |
7588563 | Guala | Sep 2009 | B2 |
7641636 | Moesli et al. | Jan 2010 | B2 |
7735664 | Peters et al. | Jun 2010 | B1 |
7762988 | Vitello | Jul 2010 | B1 |
20020133119 | Eakins et al. | Sep 2002 | A1 |
20040064095 | Vitello | Apr 2004 | A1 |
20040116858 | Heinz et al. | Jun 2004 | A1 |
20040225258 | Balestracci | Nov 2004 | A1 |